CFO Bradford Amman resigns; Roman Franklin appointed CFO via CFO Portal effective July 31, 2026

Vivos Therapeutics, Inc.

Amman receives 250,000 fully vested shares, option for 150,000 shares, and $13,333/month advisory fee for 180 days.
Franklin's CFO Portal gets $324,000 annual retainer plus $237,360 equity award; Franklin receives option for 552,000 shares.
Amman remains as transition employee for 90 days at $320,000 salary, then as independent contractor for 180 days.
If Company raises $5M+ equity, Amman's outstanding payments accelerate and options fully vest.
No disagreement cited; Amman reaffirms restrictive covenants and mutual releases exchanged.

item 1.01 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Roman Franklin

Chief Financial Officer

VVOS · Vivos Therapeutics, Inc.

Effective: 2026-07-31
Filed: August 3, 2026, 5:29 PM ET

Effective July 31, 2026, the Board appointed Roman Franklin, age 42, as the Company’s Chief Financial Officer, and designated Mr. Franklin as the Company’s principal financial officer for purposes of the Securities Exchange Act of 1934, as amended.

Departed

Bradford Amman

Chief Financial Officer and Secretary

VVOS · Vivos Therapeutics, Inc.

Effective: 2026-07-31
Successor: Roman Franklin
Filed: August 3, 2026, 5:29 PM ET

On July 31, 2026, Bradford Amman resigned as Chief Financial Officer and Secretary of the Company, and from all other officer and committee positions held by reason of his employment, effective as of that date.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Roman Franklin was appointed as Chief Financial Officer at Vivos Therapeutics, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

Effective July 31, 2026, the Board appointed Roman Franklin, age 42, as the Company’s Chief Financial Officer, and designated Mr. Franklin as the Company’s principal financial officer for purposes of the Securities Exchange Act of 1934, as amended.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Bradford Amman resigned as Chief Financial Officer and Secretary at Vivos Therapeutics, Inc..

Action: resigned
Role: Chief Financial Officer and Secretary

Exact text from the filing

On July 31, 2026, Bradford Amman resigned as Chief Financial Officer and Secretary of the Company, and from all other officer and committee positions held by reason of his employment, effective as of that date.

View on SEC.gov

Vivos Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-035867

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.